Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Wednesday, 10 February 2021 09:15

Rachel Sanborn

Written by
Dr. Sanborn is the Co-Director of the Thoracic Oncology Program and Director of the Phase I Clinical Trials Program at the Earle A. Chiles Research Institute at Providence Cancer Institute. She is a member of the Providence Institutional Review Board, the Bonnie J. Addario Lung Cancer Foundation and American Lung Association Registry Strategic Advisory Council, and the American Lung Association Medical Advisory Workgroup. She has served as co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trials Working Group and is a member of the American Society of Clinical Oncology as well as the International Association for the Study of Lung Cancer.
Wednesday, 10 February 2021 09:15

Ravi Salgia

Written by
Dr. Ravi Salgia, MD, PhD, a world-renowned expert in lung cancer, is the Chairman, and Arthur and Rosalie Kaplan Chair in Medical Oncology, and the Associate Director for Clinical Sciences Research in the City of Hope’s Comprehensive Cancer Center. Previously, he was Professor of Medicine, Pathology and Dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research at the University of Chicago. Prior to his tenure at University of Chicago School of Medicine, Dr. Salgia was faculty at the Dana-Farber Cancer Institute and Harvard Medical School following an internship and residency in internal medicine at The Johns Hopkins University School of Medicine. Dr. Salgia is named as one of the Top Doctors in America and has been honored with numerous awards including the Sun Pharma Distinguished Clinical Research Award. He is a member of the editorial board for several top Journals and has authored ~300 peer-reviewed publications and book chapters and has edited two books.
Wednesday, 10 February 2021 09:15

Hina Saeed

Written by
Dr. Hina Saeed, MD is an assistant professor in the department of radiation oncology at the Medical College of Wisconsin. Her research interests include imaging biomarkers, oligometastatic disease and tumors of the central nervous system, lung, head/neck and breast. She is passionate about health disparities with a special focus on women of color. Her interests includes use of artificial intelligence, digital health and informatics to improve cancer outcomes and cancer care delivery. Dr. Saeed is part of several programs related to clinical education and mentorship of medical students and residents. She serves on committees within the American College of Radiology (ACR), American Society for Radiation Oncology (ASTRO), Radiological Society of North America (RSNA), American Board of Radiology (ABR), American Radium Society (ARS), Society for Women in Radiation Oncology (SWRO) senior advisory panel and MR Linac Consortium. Dr Saeed is the lead moderator of social media-based radiation oncology journal club.
Wednesday, 10 February 2021 09:15

Adrian Sacher

Written by
Dr. Sacher is a medical oncologist and affiliate scientist at the Princess Margaret Cancer Centre and an assistant professor in the Departments of Medicine & Immunology at the University of Toronto. Dr. Sacher’s research focuses on novel therapeutics including immune checkpoint inhibitors, immune agonists, personalized vaccines, epigenetic therapy, adoptive cell therapy and KRAS targeted therapy.
Wednesday, 10 February 2021 09:15

Charles Rudin

Written by
Chief, Thoracic Oncology, MSKCC
Wednesday, 10 February 2021 09:15

Julia Rotow

Written by
Dr. Rotow received her M.D. from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training in Hematology/Oncology at the University of California, San Francisco. As a thoracic oncologist at the Dana-Farber Cancer Institute her research interests include the development of targeted therapies and immunotherapies for the treatment of oncogene-driven lung cancer.
Wednesday, 10 February 2021 09:15

Christian Rolfo

Written by
Christian Rolfo, MD, PhD, MBA, Dr.hc. is professor in the Division of Hematology-Oncology at University of Maryland School of Medicinethe, Director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specializes in thoracic oncology, drug development and translational oncology. Dr. Rolfo received his medical degree from the National University of Córdoba, Argentina in 1996, and University of Catania, Iatly in 2003. He completed his fellowship in Medical Oncology at University of Milan, Italy. He has earned certifications from the European Oncology Board and the Spanish and Belgian Board and spent an internship at MD Anderson Cancer Center in Houston. From 2012 to March 2018, Dr. Rolfo was the Director of Phase I - Early Clinical Trials Unit and Director of the Clinical Trials Management Program. In addition senior staff for the Thoracic Oncology Cluster at the Antwerp University Hospital in Belgium. In addition of Professor of the same University. Dr. Rolfo actively works on drug development and resistance in lung cancer and mesothelioma treatment. His focus of research are liquid biopsies (exosomes and ctDNA) and molecular profiling, he is involved in druggable biomarkers research and immunotherapy in thoracic cancer. Dr. Rolfo is the Deputy Chair of the Educational Committee of the International Association for the Study of Lung Cancer (IASLC), Vice President of The International Society of Liquid Biopsy (ISLB),Member of the Scientific Committee of the European School of Oncology (ESO). He served as Membership Committee of European Society of MedicaOncology (ESMO). He is a member of the American Society of Clinical Oncology (ASCO) the American Association of Cancer Research (AACR) and other societies. His work has been published in “New England Journal of Medicine,” “Lancet Oncology,” “Nature Nanotechnology,” "Cancer Discovery" “Journal of Thoracic Oncology” "Nature Rev Clin Oncology" among other journals. Read Dr. Rolfo's publications on PubMed. Speaking engagements include global forums on lung cancer and drug development.
Wednesday, 10 February 2021 09:15

Estelamari Rodriguez

Written by
Dr. Estelamari Rodriguez is Associate Director of Community Outreach and member of the Lung Cancer Site Disease Group of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.  She has a special interest in the early detection of lung cancer and early phase clinical trials. She earned her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital, and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain
Wednesday, 10 February 2021 09:15

Jacqulyne Robichaux

Written by
Jacqulyne Robichaux, Ph.D is a research assistant professor in the department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and she is currently an AACR-FDA Oncology Educational Fellow. She obtained her Bachelor of Science in Chemistry from Nicholls State University summa cum laude, and attained her Ph.D. in Biomedical Sciences from the Medical University of South Carolina, where she was a recipient of the distinguished graduate student award. Dr. Robichaux completed her postdoctoral training at MD Anderson in the lab of John Heymach where she identified poziotinib as an effective inhibitor of EGFR and HER2 exon 20 insertion mutations in preclinical studies. Currently, her research is focused on identifying targeted therapies for other atypical EGFR and HER2 mutations through the analysis of the structure-function relationship between inhibitor and receptor. In addition, she has ongoing research to understand mechanisms of resistance and regulation of EGFR/HER2 signaling in response to target therapies in NSCLC.
Wednesday, 10 February 2021 09:15

Naiyer Rizvi

Written by
Medical oncologist with research focus in lung cancer immunotherapy mechanisms of sensitivity and resistance
Page 361 of 371